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Abstract
In December of 2013, chikungunya virus (CHIKV), an alphavirus in the family Togaviridae,
was introduced to the island of Saint Martin in the Caribbean, resulting in the first autochtho-
nous cases reported in the Americas. As of January 2015, local and imported CHIKV has
been reported in 50 American countries with over 1.1 million suspected cases. CHIKV
causes a severe arthralgic disease for which there are no approved vaccines or therapeu-
tics. Furthermore, the lack of a commercially available, sensitive, and affordable diagnostic
assay limits surveillance and control efforts. To address this issue, we utilized an insect-
specific alphavirus, Eilat virus (EILV), to develop a diagnostic antigen that does not require
biosafety containment facilities to produce. We demonstrated that EILV/CHIKV replicates to
high titers in insect cells and can be applied directly in enzyme-linked immunosorbent
assays without inactivation, resulting in highly sensitive detection of recent and past CHIKV
infection, and outperforming traditional antigen preparations.
Author Summary
We have developed an innovative approach to production of alphavirus antigens for use in
diagnostic assays that results in reduced production complexity as well as improved sensi-
tivity in application. By generating recombinant viruses that contain the structural protein
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genes of pathogenic alphaviruses and the nonstructural protein genes of an insect-specific
alphavirus, Eilat virus, we have been able to produce insect-restricted viruses that are anti-
genically identical to their pathogenic counterparts. The insect-specific nature of these chi-
meric viruses yields an advantageous safety profile and allows for safe handling of the
antigen at the bench top. Traditional antigens, produced from wild-type virus, require
extensive processing, from growth at biosafety level 3 to concentration and inactivation,
followed by lyophilization, which often compromises antigen reactivity and is financially
costly. Furthermore, current inactivation methods are imperfect processes that have his-
torically resulted in residual live virus and subsequent breach of containment when used
in a diagnostic setting. Other approaches, such as recombinant antigens generated from
viral particle subunits, are missing conformational epitopes and their application results in
reduced sensitivity. Here we describe the development of a diagnostic assay using this
technology for the detection of chikungunya infection in humans.
Introduction
The genus Alphavirus in the family Togaviridae is comprised of small, enveloped viruses with
single-stranded, positive-sense RNA genomes 11–12 kb in length [1]. The genus includes 31
recognized species classified into eleven complexes based on antigenic and/or genetic similari-
ties [2–4], with most utilizing mosquitoes as vectors [1–7]. Mosquito-borne alphaviruses can
infect mosquito species encompassing at least eight genera as well as many vertebrate taxa [8–
12]. This ability to infect vertebrates and mosquitoes enables the maintenance of alphaviruses
in endemic cycles with sporadic spillover events into human populations. Infections by Old
World alphaviruses including chikungunya (CHIKV), o'nyong-nyong, Sindbis, and Ross River
viruses can produce rash and debilitating arthralgia [13]. In contrast, NewWorld alphaviruses
such as western (WEEV), eastern, and Venezuelan equine encephalitis (VEEV) viruses can
cause fatal encephalitis [13].
In 2004, CHIKV reemerged from Africa and spread to the Indian Ocean Basin, Asia, and
Europe causing explosive epidemics affecting millions of people [14–20]. Chikungunya fever
(CHIKF) is characterized by severe, debilitating, and often chronic arthralgia that can persist
for years, resulting in major economic as well as public health impacts [18,20–22]. Additionally,
CHIKF is not easily diagnosed due to the overlap in initial signs and symptoms with dengue,
malaria and other acute febrile illnesses, as well as the lack of high quality, affordable, commer-
cially-available diagnostic assays [23,24].
In October of 2013, CHIKV arrived in the Caribbean from Asia or Oceania and spread to
South, Central and North America, resulting in over 1.1 million suspected cases as of February
2015 [Pan American Health Organization (PAHO) data]. Over 2,000 imported CHIKF cases
have been detected in the U.S. and transmission in Florida has resulted in 11 autochthonous
cases. Transmission in other parts of the U.S. is expected as CHIKV moves northward through
Mexico. The large populations of both urban mosquito vectors (Aedes aegypti and A. albopic-
tus) throughout most of the Americas, large populations of naive people, and its history in
Southeast Asia indicate that CHIKV is likely to remain epidemic and endemic in the Americas
for the foreseeable future [25].
Recently, a related alphavirus, Eilat virus (EILV), isolated from Anopheles coustani s.I. mos-
quitoes was described [26]. EILV groups phylogenetically within the mosquito-borne clade of
alphaviruses as a sister to the WEE complex. Although EILV, like other alphaviruses, can repli-
cate to high titers (>108 PFU/mL) in mosquito cells, it is unable to replicate in vertebrate cells
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with blocks at both attachment/entry as well as viral RNA replication levels [27]. These unique
EILV characteristics as well as the genetic tractability of alphaviruses provide an opportunity to
safely develop antigens that, in contrast to traditional methods, do not require inactivation or
expensive containment facilities to produce. Here, we report the development of an EILV/
CHIKV chimera and its use as a diagnostic reagent to detect CHIKV infection in humans.
Methods
Cell culture
C7/10 cells (American Type Culture Collection, Rockville, MD), derived from A. albopictus
mosquitoes, were propagated at 28°C with 5% CO2 in Dulbecco’s minimal essential medium
(DMEM) containing 10% (V/V) fetal bovine serum (FBS), sodium pyruvate (1 mM), penicillin
(100 U/mL), streptomycin (100 μg/mL), and 1% (v/v) tryptose phosphate broth (Sigma,
St. Louis, MO).
cDNA clone and rescue of infectious EILV/CHIKV
An infectious cDNA clone encoding the EILV genome was chimerized by replacing its struc-
tural polyprotein open reading frame with that of a human CHIKV isolate from the British
Virgin Islands (strain-99659) [26, 28]. The chimera was cloned and rescued as previously
described [27]. Briefly, the CHIKV structural polyprotein open reading frame (ORF) was
reverse transcribed from extracted RNA and PCR-amplified in three fragments between AvrII,
Bsu36I, NcoI, and NotI restriction sites. These fragments were then digested and ligated into
an infectious clone of EILV described previously [26] between AvrII and NotI sites, replacing
the structural polyprotein ORF of EILV.
Virus amplification
The EILV/CHIKV chimera was amplified by infection of C7/10 cells at a multiplicity (MOI) of
0.1 PFU/cell and at 48 hours post-infection (hpi), supernatants were harvested and clarified by
centrifugation for 10 min at 3,000 × g. To generate serum-free EILV/CHIKV for use in indirect
enzyme-linked immunosorbent assays (ELISAs), C7/10 monolayers were washed with PBS 6
hours post-infection, and VP-SFM medium (GIBCO, Grand Island, NY) containing penicillin
(100 U/mL), streptomycin (100 μg/mL), and 1% (v/v) tryptose phosphate broth (Sigma) was
added. Cells were incubated for an additional 42 hours and supernatants were harvested and
stored at -80°C.
To compare EILV/CHIKV as antigen to a traditional antigen preparation, CHIKV (strain
LR2006 OPY1), obtained from the World Reference Center for Emerging Viruses and Arbovi-
ruses (WRCEVA) at the University of Texas Medical Branch, was amplified by infection of
confluent BHK-21 cells, and cell-lysate antigen (CLA) was prepared as previously described
[29]. Briefly, infected cells were pelleted, washed with ice-cold borate saline buffer, and resus-
pended in an SDS/Triton X-100 buffer for sonication, followed by clarification by centrifuga-
tion and inactivation with 0.3% (v/v) β-propiolactone.
Mouse antisera and antibodies
Mouse immune ascitic fluids (MIAFs) against CHIKV strain Ross T-36059, and Gamboa virus
strain T-34953, a bunyavirus used as a negative control, were obtained from the WRCEVA.
Mouse immune serum (MIS) raised against mosquito salivary proteins was generated as previ-
ously described [30]. Briefly, adult CD1 mice were naturally exposed to approximately 20 A.
albopictusmosquito bites twice weekly for 4 weeks, at which point serum was collected for use
Chikungunya ELISA Utilizing Eilat-Based Antigen
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004119 October 22, 2015 3 / 16
in an ELISA. A mouse IgG monoclonal antibody (mAb) against CHIKV, CHK-175, was used
as a quantitative benchmark [31].
Human antisera and antibodies
For IgM ELISA positive controls, a panel of five IgM/ELISA- and PRNT-positive convalescent
sera obtained from patients diagnosed by reverse transcriptase-PCR with CHIKV infection was
used. Eight human serum samples positive for either dengue virus (DENV) or VEEV but nega-
tive for CHIKV by hemagglutination inhibition (HI) [32] were used as negative controls. To
validate IgM ELISAs, a panel of acute serum samples collected from patients in Mexico with
suspected CHIKV infection, based on clinical guidelines set forth by the Centers for Disease
Control and Prevention (CDC) and PAHO [33], were characterized by plaque reduction neu-
tralization test (PRNT) as described previously [32]. Thirty-two CHIKV PRNT-positive sam-
ples were then selected for comparative IgM ELISA.
For IgG ELISAs, 32 CHIKV PRNT-positive samples from Bangladesh, collected for a sero-
prevalence study from healthy individuals, were used. To determine a statistically robust cut-
off value for human antibody-capture ELISAs, a panel of 34 human serum samples from Ban-
gladesh, negative for CHIKV by PRNT, was utilized in addition to the 8 negative control sam-
ples described above.
Indirect IgG ELISAs
Immulon 2HB 96-well plates (Fisher Scientific, Pittsburgh, PA) were coated with serum-free
EILV/CHIKV culture supernatants diluted in PBS, to a final concentration of 5 x 104 PFU per
well or with CLA at a 1:400 dilution and incubated overnight at 4°C. These antigen dilutions
were optimized in titration experiments against polyclonal sera. Plates were blocked with
100 μL of InBlock buffer (InBios, Inc., Seattle, WA) for 1 h at room temperature (RT) and
washed 5 times with 300 μL of 0.1% Tween-20 in PBS using an automatic plate washer
(BIO-RAD, Model 1575 ImmunoWash, Hercules, CA). Serum samples were diluted 1:100 in
EB-C sample dilution buffer (SDB; InBios) and 2-fold serial dilutions were added to plates fol-
lowed by incubation for 1 h at RT. Plates were washed as described above, and 50 μL of biotin-
conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA)
were added at a dilution of 1:10,000 in SDB and plates were incubated for 1 h at RT. Then,
plates were washed, and 50 μL streptavidin-conjugated horseradish peroxidase (HRP) (Roche
Diagnostics, Indianapolis, IN) were added at a dilution of 1:10,000 in SDB, and plates were
incubated for 1 h at RT. Plates were washed and 75 μL of 3,3’,5,5’-tetramethylbenzidine sub-
strate (TMB; Sigma) were added, incubated for 10 min at RT, and the reaction was stopped
with 50 μL of 0.5M sulfuric acid. Absorbance values were read at 450 nm on a VERSAmax tun-
able microplate reader (Molecular Devices, Sunnyvale, CA).
CHIKV IgM- and IgG-capture ELISAs
Human serum samples, diluted 1:100 in SDB, were added to human IgM- or IgG-capture
96-well microtiter plates (InBios) in 50 μL volumes. After 1 h incubation at 37°C, plates were
washed as described above. Cell supernatant containing EILV/CHIKV diluted in 1% BSA in
PBS to a concentration of 2.5X107 PFU/well was then added and incubated for 1 h at 37°C.
A panel of eight anti-CHIKV mouse mAbs was tested independently or in combinations for
activity in a capture ELISA. CHK-175 antibody produced the highest signal-to-noise ratio at an
optimal concentration of 100 ng/well and was selected for further use as the detecting antibody.
CHK-175 diluted in SDB to 100 ng/well was added and incubated for 1 h at 37°C. Plates were
washed, 50 μL of goat anti-mouse IgG-HRP conjugated antibody (Southern Biotech,
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Birmingham, AL) diluted 1:5,000 in conjugate dilution buffer (InBios) were added, and plates
were incubated for 1 h at 37°C. Plates were then washed, 75 μL of TMB was added, incubated
for 10 min at RT, and the reaction was stopped by the addition of 50 μL 0.5M sulfuric acid. The
absorbance values were read at 450 nm.
Commercially available anti-CHIKV IgM (ab177848, Lot: GR195090-3, Abcam, Cambridge,
MA) and anti-CHIKV IgG Human ELISA Kits (ab177835, Lot: GR148047-1, Abcam) were
used according to manufacturer’s instructions.
Stability of EILV/CHIKV
The stability of EILV/CHIKV was assessed as described previously [34]. EILV/CHIKV was
diluted 1:2 in PBS with 1% BSA, TRIS with 1% BSA, or SDB and incubated at 37°C. Antigen
was sampled at 0, 3, 7, or 10 days post-incubation and the antigen stability was assessed in
IgM-capture ELISA described above. The stability was compared to a 4°C control of EILV/
CHIKV and percent of original activity was calculated.
Animal safety study
Pregnant CD1 mice were obtained from Charles River (Wilmington, MA). Seven-day-old
suckling mice were pooled and randomly distributed into three groups of 13 mice each and
inoculated intracranially (IC) with either 8 log10PFU of EILV/CHIKV, 4 log10PFU of live-
attenuated CHIKV strain 181/25 [35] as a positive control for replication and neurovirulence,
or mock-infected with PBS. Animals were observed daily for 28 days and sacrificed when they
became moribund. Three mice per group were sacrificed on 0, 3, 7, and 14 days post-infection
and brain tissue was collected to determine infectious virus content via plaque assay on C7/10
cells as previously described [26].
Statistical analysis
To compare the activities of EILV/CHIKV versus CLA in indirect ELISAs, and the effects of
the EILV/CHIKV and Abcam methods on absorbance values and signal-to-noise ratios, a
2-way ANOVA using a Bonferroni post-hoc test was performed. To compare the effects of dif-
ferent buffer preparations on EILV/CHIKV stability and activity differences between high-,
medium-, and low-positive serum groups tested using either EILV/CHIKV or Abcam ELISA, a
2-way ANOVA using Tukey’s multiple comparisons test was performed. All statistical calcula-
tions were performed in Prism 6 (GraphPad Software, Inc., La Jolla, CA). A cut-off absorbance
value for CHIKV-positive human samples was calculated as 5 standard deviations above the
mean absorbance value of 42 PRNT-negative human serum samples.
Ethics statement
Deidentified, excess diagnostic serum samples, fromMexico and Bangladesh, were tested
under a University of Texas Medical Branch institutional review board-approved protocol with
no informed consent required. Animal studies were approved by the UTMB Institutional Ani-
mal Care and Use Committee under protocol 02-09-068. The euthanasia method employed
was carbon dioxide exposure followed by decapitation.
Results
Evaluation of EILV/CHIKV as an antigen in indirect ELISA
The utility of the EILV/CHIKV chimeric virus as a diagnostic antigen was first tested in an
indirect ELISA. Plates were coated with EILV/CHIKV at 5 x 104 PFU per well and antigen was
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detected by both polyclonal and monoclonal antibodies with dilutions from 1:50 to 1:51,200.
EB-C sample dilution buffer, anti-Gamboa MIAF, and MIS raised against mosquito salivary
proteins were utilized as negative controls. No cross-reactivity with mosquito-sensitized mouse
sera was observed and optical density (OD) values of all of the negative controls were 0.07
(Fig 1A). In contrast, the mouse anti-CHIKV polyclonal antisera and CHK-175 monoclonal
antibody readily detected antigen at all dilutions with OD values from 1.1–3.2 and 0.2–2.7,
respectively. Signal-to-noise ratios ranged from ~16–46:1 and ~3–39:1 for polyclonal and
monoclonal antibodies, respectively. As antigen was detected at all serum dilutions, an esti-
mated quantitative sensitivity of the EILV/CHIKV ELISA was determined by titrating CHK-
175 antibody from 100 μg/mL to 98 ng/mL. The lowest concentration of 98ng/mL was capable
of detecting antigen, indicating a very high sensitivity of the assay.
In contrast to the results obtained with EILV/CHIKV, CLA could only be detected by the
polyclonal sera (Fig 1B). In addition, the OD values obtained with polyclonal sera ranged from
0.1–2.7 and were significantly lower at all dilutions (p<0.05).
Utilization of the EILV/CHIKV as antigen to detect human IgM and IgG in
capture ELISA
EILV/CHIKV antigen was assessed as a diagnostic reagent in a capture ELISA format. IgM-
and IgG-capture ELISAs were performed with acute serum samples collected 8 days post-fever
onset from patients with RT-PCR-confirmed CHIKV infection. Samples positive for DENV or
VEEV (IAB subtype) but negative for CHIKV by HI were utilized as negative controls. Serum
samples were diluted from 1:50 to 1:51,200 and added to IgM- or IgG-capture plates followed
by the addition of EILV/CHIKV. Antigen was detected with mouse CHK-175 mAb. Anti-
CHIKV IgM was readily detected with OD values ranging from 0.23–3.0, whereas the negative
controls yielded a mean OD value of 0.09 (Fig 2A). Signal-to-noise ratios ranged from 2–45:1
for all dilutions except 1:51,200. Anti-CHIKV IgG was also readily detected with OD values
ranging from 1.6–2.6, with negative controls yielding a mean OD value of 0.09 (Fig 2B). Signal-
to-noise ratios ranged from 24–39:1. No cross-reactivity was observed in either IgM- or IgG-
capture ELISAs with anti-VEEV or-DENV human serum.
Fig 1. Indirect mouse anti-CHIKV IgG ELISAs utilizing either (A) EILV/CHIKV or (B) cell-lysate antigen to detect serially diluted polyclonal anti-
CHIKVMIAF (measured over a range of serum dilutions, red) or monoclonal antibody CHK-175 (expressed in ng quantities, blue).MIAF against
Gamboa virus and MIS against mosquito antigens were included as negative controls. Mean and standard deviation of 2 replicates are reported.
doi:10.1371/journal.pntd.0004119.g001
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Next, we compared the IgM- and IgG-capture ELISAs utilizing EILV/CHIKV antigen to
commercial human IgM- or IgG-capture ELISA Kits (Abcam). A panel of human serum sam-
ples from suspected CHIKV-infected individuals in Mexico was screened by PRNT50 and 32
positive samples were selected for IgM ELISAs. A PRNT50 was utilized, instead of PRNT80, to
increase the dynamic range of the assay to allow for more sensitive detection of anti-CHIKV
antibodies in the acute phase of disease. For IgG ELISAs, 32 PRNT80-positive samples from
Bangladesh, collected from healthy individuals, were selected. Serum samples, 4 positive and 8
negative, used above were selected as controls for both IgM and IgG ELISAs. The negative con-
trols were confirmed CHIKV-negative by HI, and some were positive for either DENV or
VEEV by HI. To determine a cut-off value for the IgM and IgG ELISAs, 42 human serum sam-
ples negative by CHIKV PRNT80 were utilized (S1 Table). The OD values ranged from 0.06–
0.16 and 0.08–0.12 for IgM and IgG ELISAs, respectively, and cut-off values of 0.18 and 0.13
were determined as 5 standard deviations above the mean absorbance value. For the Abcam
IgM and IgG kits, positive samples were determined as per the manufacturer’s protocol.
The EILV/CHIKV IgM ELISA detected all 32 PRNT50-positive serum samples (100% sensi-
tivity), whereas the Abcam kit yielded positive results for only 13 (41% sensitivity), 11 of which
had PRNT50 titers>640 (Table 1). An additional 12 of the 32 samples were inconclusive as per
instructions provided with the Abcam kit. The 24 samples with PRNT50>640 yielded the high-
est OD values in EILV/CHIKV IgM ELISA ranging from 1.0–3.3, and signal-to-noise ratios
were 11–36:1. In contrast, the OD values of 11 samples positive with the Abcam kit ranged
from 0.54–0.7, with signal-to-noise ratios of 2.7–3.5:1. Additionally, the EILV/CHIKV IgM
ELISA distinguished between samples with PRNT50 > 640 versus 320, whereas no differ-
ences could be discerned with the Abcam kit, which detected only 2 of 8 samples with PRNT50
 320 (Fig 3A and 3B).
The EILV/CHIKV IgG ELISA detected all 32 PRNT80-positive serum samples (100% sensi-
tivity), whereas the Abcam kit detected only 23 (72% sensitivity) (Table 2). The Abcam kit
detected all 12 samples with PRNT80 >640, whereas it could only detect 7 out of 10, and 4 out
of 10 samples with PRNT80 160–320, and<80, respectively. Additionally, 3 samples were
inconclusive as per the manufacturer’s instructions, and one of the negative controls tested
positive with the Abcam kit. The positive samples produced similar OD values in both kits;
Fig 2. Human anti-CHIKV antibody-capture ELISAs utilizing EILV/CHIKV as antigen to detect either (A) IgM or (B) IgG antibodies (both measured
over a range of serum dilutions, red).Human serum samples that were antibody-positive for either DENV or VEEV but negative for CHIKV by HI were
included as negative controls. Mean and standard deviations of 2 replicates are reported.
doi:10.1371/journal.pntd.0004119.g002
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Table 1. Comparative IgM ELISA results using EILV/CHIKV and Abcammethods.

















SW1214 NA <20 0.07 0.19 NA NA - -
358010P NA <20 0.08 0.23 NA NA - -
JL07301 NA <20 0.07 0.18 NA NA - -
CK08300 NA <20 0.08 0.2 NA NA - -
NR09270 NA <20 0.1 0.22 NA NA - -
5343–12 NA <20 0.16 0.17 NA NA - -
5343–14 NA <20 0.13 0.2 NA NA - -
RT09270 NA <20 0.07 0.17 NA NA - -
CH-0027 3 <20* 0.21 0.37 2 2 + -
CH-0010 3 <20† 0.21 0.21 2 1 + -
LI-0007 4 80 0.29 0.31 3 2 + -
CH-0024 5 80 1.16 0.64 12 3 + +
LI-0003 3 160 0.2 0.32 2 2 + -
TA-0001 4 320 1.83 0.56 19 3 + +
LI-0004 6 320 1.18 0.45 12 2 + ?
LI-0027 10 320 0.6 0.37 6 2 + -
LI-0023 1 >640 2.78 0.45 29 2 + ?
CH-0068 4 >640 2.14 0.49 23 3 + ?
LI-0021 4 >640 3.28 0.66 35 3 + +
LI-0002 5 >640 1.79 0.52 19 3 + ?
LI-0030 6 >640 3.23 0.6 34 3 + +
CH-0013 6 >640 3.28 0.55 35 3 + +
CH-0007 6 >640 3.31 0.55 35 3 + +
CH-0069 7 >640 2.32 0.39 24 2 + -
CH-0043 7 >640 2.65 0.53 28 3 + ?
CH-0042 8 >640 1.03 0.41 11 2 + -
CH-0066 8 >640 2.11 0.53 22 3 + ?
LI-0025 9 >640 2.69 0.53 28 3 + ?
CH-0036 10 >640 2.8 0.54 29 3 + +
LI-0015 10 >640 3.23 0.55 34 3 + +
CH-0062 10 >640 3.25 0.57 34 3 + +
CH-0049 11 >640 3.23 0.48 34 2 + ?
LI-0017 13 >640 1.72 0.47 18 2 + ?
CH-0057 13 >640 3.24 0.52 34 3 + ?
CH-0050 13 >640 3.31 0.53 35 3 + ?
CH-0063 14 >640 3.23 0.56 34 3 + +
CH-0058 17 >640 3.21 0.7 34 4 + +
CH-0018 20 >640 3.33 0.69 35 4 + +
CH-0041 >640 2.77 0.47 29 2 + ?
CH-0032 >640 3.21 0.54 34 3 + +
Pos 1 NA NT 3.15 0.55 33 3 + +
Pos 2 NA NT 2.33 0.35 25 2 + -
Pos 3 NA NT 3.26 0.54 34 3 + +
(Continued)
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however differences in OD values of negative controls were observed with OD values ranging
from 0.09–0.12 in the EILV/CHIKV ELISA compared to 0.14–0.49 in the Abcam ELISA. Con-
sequently, significant differences in signal-to-noise ratios between EILV/CHIKV and Abcam
ELISAs for high (p<0.0001) and medium (p<0.05) PRNT80 groups were observed. For high-
positive samples with PRNT80 >640, EILV/CHIKV ELISA ratios ranged from 7–17:1 and
2–5:1 in the Abcam ELISA (Fig 4A and 4B). For medium-positive samples with PRNT80 160–
320, the ratios ranged from 3–8:1 in the EILV/CHIKV ELISA and 1–3:1 in the Abcam ELISA.
No differences between EILV/CHIKV and Abcam ELISAs were observed in signal-to-noise
ratios of samples with PRNT80 <80.
Stability of EILV/CHIKV antigen
Using the accelerated decay methodology [34], EILV/CHIKV was tested for its stability in
three different buffers. EILV/CHIKV antigen was relatively stable in IgM-capture ELISA, with
mean activity values, relative to initial activity, of 90% at 3 days, 87% at 7 days, and 82% at 10
days at 37°C in PBS-based buffer containing 1% BSA (Fig 5). In contrast, commercial kits gen-
erally provide antigen in lyophilized form and, upon reconstitution in buffer, as stated in their
Table 1. (Continued)

















Pos 4 NA NT 0.92 0.28 10 1 + -
* 44% reduction in plaques.
† 37% reduction in plaques.
OD, optical density. EILV, Eilat virus. CHIKV, chikungunya virus.
NA, not applicable. NT, not tested. +, positive result.–, negative result.?, inconclusive result.
doi:10.1371/journal.pntd.0004119.t001
Fig 3. Comparison of EILV/CHIKV and Abcam human anti-CHIKV IgM-capture ELISAmethods. (A) raw OD values or (B) signal-to-noise ratios
(calculated by dividing positive sample OD values by mean negative control OD value) produced by samples of varying degrees of seropositivity were
compared. Low-positive samples had PRNT50 80 (n = 4), medium-positive samples had PRNT50 160–320 (n = 4), and high-positive samples had PRNT50
>640 (n = 24). Mean and standard deviations are reported. A 2-way ANOVA with Tukey’s test was used to compare absorbance values and signal-to-noise
ratios within each ELISA method. 2-way ANOVA with Bonferroni’s test was used to compare absorbance values and signal-to-noise ratios between each
ELISAmethod.
doi:10.1371/journal.pntd.0004119.g003
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Table 2. Comparative IgG ELISA results using EILV/CHIKV and Abcammethods.












SW1214 NT 0.12 0.14 NA NA - -
358010P NT 0.09 0.25 NA NA - -
JL07301 NT 0.09 0.49 NA NA - +
CK08300 NT 0.09 0.27 NA NA - -
NR-
09270
NT 0.09 0.21 NA NA - -
5343–12 NT 0.08 0.31 NA NA - -
5343–14 NT 0.09 0.30 NA NA - -
RT09270 NT 0.10 0.14 NA NA - -
61106 40 0.68 0.69 7 3 + +
62901 40 0.39 0.40 4 2 + +
100103 40 0.26 0.28 3 1 + -
110303 40 0.23 0.24 2 1 + -
80305 80 0.21 0.22 2 1 + -
82202 80 0.41 0.34 4 1 + ?
100305 80 0.40 0.38 4 1 + +
102204 80 0.34 0.33 4 1 + ?
131201 80 0.33 0.38 4 1 + +
142201 80 0.25 0.27 3 1 + -
81108 160 0.62 0.62 7 2 + +
100306 160 0.48 0.47 5 2 + +
132201 160 0.58 0.48 6 2 + +
161101 160 0.31 0.27 3 1 + -
252101 160 0.32 0.27 3 1 + -
10502 320 0.36 0.31 4 1 + ?
11102 320 0.51 0.47 5 2 + +
11303 320 0.76 0.72 8 3 + +
21204 320 0.73 0.67 8 3 + +
50503 320 0.77 0.88 8 3 + +
140403 >640 0.66 0.66 7 3 + +
141201 >640 1.16 0.92 12 3 + +
142302 >640 1.31 1.06 14 4 + +
142303 >640 0.97 0.78 10 3 + +
150101 >640 0.72 0.60 8 2 + +
152203 >640 0.68 0.69 7 3 + +
161203 >640 0.94 0.81 10 3 + +
170404 >640 0.75 0.76 8 3 + +
211202 >640 1.23 1.03 13 4 + +
232103 >640 1.58 1.21 17 5 + +
362101 >640 1.26 0.94 13 4 + +
401202 >640 1.10 0.90 12 3 + +
Pos 1 NT 2.32 1.61 25 6 + +
Pos 2 NT 0.82 0.40 9 2 + +
Pos 4 NT 1.58 1.01 17 4 + +
Pos 5 NT 0.75 0.86 8 3 + +
OD, optical density. EILV, Eilat virus. CHIKV, chikungunya virus.
NA, not applicable. NT, not tested. +, positive result.–, negative result.?, inconclusive result.
doi:10.1371/journal.pntd.0004119.t002
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protocol, the antigen remains stable for up to 24 hours at 2–8°C. While there was no difference
in ELISA activity for EILV/CHIKV stored in PBS (1% BSA) versus SDB at the later time points
of 7 and 10 days at 37°C, antigen stored in TRIS (1% BSA) was less stable than that stored in
the other two buffers at all time points.
Fig 4. Comparison of EILV/CHIKV and Abcam human anti-CHIKV IgG-capture ELISAmethods. (A) raw OD values or (B) signal-to-noise ratios
(calculated by dividing positive sample OD values by mean negative control OD value) produced by samples of varying degrees of seropositivity were
compared. Low-positive samples had PRNT80 80 (n = 10), medium-positive samples had PRNT80 160–320 (n = 10), and high-positive samples had
PRNT80 >640 (n = 10). Means and standard deviations are reported. A 2-way ANOVA with Tukey’s test was used to compare absorbance values and signal-
to-noise ratios within each ELISAmethod. 2-way ANOVA with Bonferroni’s test was used to compare absorbance values and signal-to-noise ratios between
each ELISAmethod.
doi:10.1371/journal.pntd.0004119.g004
Fig 5. Stability of EILV/CHIKV in different buffers determined by accelerated decay at elevated temperature.Mean and standard deviations of three
replicates are reported. A 2-way ANOVA with Tukey’s test was used to compare the effects of different buffer preparations on ELISA activity.
doi:10.1371/journal.pntd.0004119.g005
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Safety of EILV/CHIKV in vivo
Infant mice inoculated IC with 8 log10PFU of EILV/CHIKV showed no signs of disease while
those infected with a 10,000-fold lower dose of live-attenuated vaccine strain 181/25 did show
signs of disease, including hind limb paralysis, hunched posture, and ruffled fur (Fig 6A). In
terms of replication, infectious titer of EILV/CHIKV dropped from a mean titer of 1.7X107
PFU/mL at day 0 to 1.3X102 PFU/mL at day 3, and could not be detected on day 7. As expected,
positive control strain 181/25 replicated from a mean titer of 9.3X102 PFU/mL on day 0 to
3.1X107 PFU/mL on day 3 (Fig 6B).
Discussion
Our results indicate that EILV/CHIKV serves as a cost effective ELISA antigen for serological
detection of CHIKV infection. In mosquito cells, this chimera replicates to exceptionally high
titers (1010 PFU/mL), including in serum-free medium. Using a highly sensitive, newborn
mouse model, we have demonstrated the replication-incompetence and safety of EILV/CHIKV
following IC inoculation. The safety characteristics of EILV/CHIKV eliminate the need for
high-level biosafety containment facilities for antigen production, and chemical or physical
inactivation, thus maximally preserving native antigens. When applied either in capture- or
indirect-ELISA formats using control MIAFs and acute and convalescent human serum sam-
ples from the Caribbean and Bangladesh, respectively, we determined that the EILV/CHIKV-
based assay provides extremely sensitive indication of infection, outperforming traditional
antigens with very high signal-to-noise ratios.
While there are no licensed antiviral treatments available for CHIKV infection, early diag-
nosis is nevertheless important. Currently, patients lacking a laboratory-confirmed diagnosis
are often empirically treated with antibiotics or antimalarials due to similar clinical presenta-
tions [40]. This can contribute to antimicrobial resistance and unnecessary side effects. In
terms of surveillance, early and simple detection of CHIKV infection in resource-poor regions
can better inform vector control measures, limiting epidemic spread of disease. Also, distin-
guishing dengue, which can be life threatening, from CHIKV infection can be important for
case management.
Fig 6. Safety of EILV/CHIKV in the newbornmousemodel of neurovirulence. (A) Survival of infant mice infected IC with EILV/CHIKV, live-attenuated
vaccine strain 181/25, or PBS. (B) Replication of EILV/CHIKV or strain 181/25 in newborn mouse brain tissue.
doi:10.1371/journal.pntd.0004119.g006
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To detect recent CHIKV infections, IgM ELISAs are effective due to the prompt production
following infection (usually within 4–7 days) of virus-specific IgM [16]. Additionally, IgM
tends to be less cross-reactive among alphaviruses than IgG, resulting in high specificity [36].
Although RT-PCR is effective for diagnosing CHIKF soon after infection, its utility diminishes
with time after the onset of signs and symptoms. Typically, by day 5 after symptoms appear,
viral RNA levels in serum or plasma fall below detection limits [16].
Several commercial kits are available for the detection of anti-CHIKV IgM antibodies. How-
ever, their lack of specificity and sensitivity limits their clinical use [36]. Current PAHO, World
Health Organization, and CDC guidelines recommend that in-house IgM ELISAs be imple-
mented for accurate CHIKF diagnostics, and the use of whole virus antigen as opposed to
recombinant subunits is recommended [33]. Of the commercial kits, Abcam’s Anti-CHIKV
IgM Human ELISA kit is reported to produce comparable results to the CDC IgM ELISA [33].
In our comparative analysis, the EILV/CHIKV IgM ELISA demonstrated improved sensitivity
with a maximum signal-to-noise ratio of 35:1 compared to a maximum ratio of 4:1 for the
Abcam kit. Overall, the signal-to-noise ratios of the EILV/CHIKV IgM ELISAs were consis-
tently higher than those produced by the Abcam kit. In laboratories that lack access to plate
readers to quantify optical density, high signal-to-noise ratios can aid in the differentiation of
positive and negative samples by simple visual observation.
Of the 32 positive controls that we tested, 6 were collected between 4 and 5 days after the
onset of symptoms. Of those, 5 had signal-to-noise ratios of 12–35:1, allowing for confident
identification of CHIKV IgM-positivity without the need for a plate reader. Samples collected
less than 4 days after onset would require the use of a plate reader. For reliable detection of
acute CHIKV-infection, EILV/CHIKV IgM-capture ELISA can be used alone, or in conjunc-
tion with, reverse transcriptase-PCR testing.
Traditional approaches to antigen production for alphaviruses require infection of cell cul-
tures or mouse brains in biosafety facilities, followed by time-consuming and expensive proce-
dures to purify, concentrate, and inactivate the virus [37]. Manipulations such as these also
have the potential to adversely affect the antigen, resulting in loss of epitopes. For instance, our
mouse anti-CHIKV mAb readily detected EILV/CHIKV-derived antigen but not that derived
from CLA (Fig 1). Recently, it was reported that complete CHIKV inactivation while retaining
acceptable ELISA activity requires gamma-irradiation, followed by β-propiolactone-inactiva-
tion [38]. Furthermore, such preparations are unstable at 4°C, requiring that the antigen be
lyophilized for storage longer than 24 hours [38]. As a result, the cost of antigen production
from CHIKV cultures can be high and many of the commercially available ELISA kits are pro-
hibitively expensive for clinical laboratories in developing countries endemic for alphaviruses.
Recombinant protein antigens, derived from cloning and expressing partial viral genomes, can
sometimes be missing critical conformational epitopes or may not fold correctly during pro-
duction, resulting in serologic reduced sensitivity. Virus-like particle antigens, on the other
hand, should contain conformational epitopes, but concentration and purification steps can
complicate production [41]. Using the EILV chimeric platform, the cost of production can be
reduced by eliminating the need for containment, purification, concentration, and inactivation.
EILV/CHIKV also displays remarkable stability in liquid buffer, with an estimated shelf life at
4°C of>1 year. These qualities suggest that EILV-based chimeras are superior to traditional
inactivated virus antigens for alphavirus diagnostics.
While we have shown the utility of an EILV-based chimera as an ELISA antigen, further
testing and evaluation is needed to define parameters for the clear discrimination between posi-
tive and negative results. We have shown that our anti-CHIKV IgM and IgG ELISAs can dis-
tinguish between human infections caused by CHIKV and VEEV or DENV with a high degree
of signal separation. However, because other closely related alphaviruses co-circulate in most if
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not all CHIKF-endemic regions (e.g. Mayaro virus in South America [39]), more extensive test-
ing is needed to rule out false positives due to cross-reactivity with antibodies elicited by other
alphaviruses, and thus determine the specificity of this assay. Also, while we have performed
accelerated-decay studies to evaluate the stability of EILV/CHIKV in liquid storage, real-time
stability studies need to be performed to determine the long-term stability of the antigen at
4°C.
Supporting Information
S1 Table. Optical density values of serum samples negative by PRNT used to calculate cut-
off values for IgM and IgG ELISAs.
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